Hyperfine (HYPR) Cash from Investing Activities Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Cash from Investing Activities Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -208.79% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -397.90% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -514.25% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -187.82% |
| 10 | Hyperfine | 94.51 Mn | 53.23 Mn | 1.98 Mn | 48.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.73% |
| Dec 31, 2025 | -687.50% |
| Sep 30, 2025 | 18.24% |
| Jun 30, 2025 | -632.39% |
| Mar 31, 2025 | -225.52% |
| Dec 31, 2024 | 96.90% |
| Sep 30, 2024 | 39.54% |
| Jun 30, 2024 | 68.02% |
| Mar 31, 2024 | -137.70% |
| Dec 31, 2023 | -63.29% |
| Sep 30, 2023 | -52.02% |
| Jun 30, 2023 | -511.11% |
| Mar 31, 2023 | 80.19% |
| Dec 31, 2022 | 83.79% |
| Sep 30, 2022 | 83.69% |
| Jun 30, 2022 | 110.69% |
| Mar 31, 2022 | -81.18% |